Compare CLW & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLW | FULC |
|---|---|---|
| Founded | 1926 | 2015 |
| Country | United States | United States |
| Employees | 3710 | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.1M | 285.4M |
| IPO Year | 2008 | 2019 |
| Metric | CLW | FULC |
|---|---|---|
| Price | $20.33 | $3.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $20.33 | $16.38 |
| AVG Volume (30 Days) | 122.9K | ★ 1.6M |
| Earning Date | 04-28-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,555,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.42 | N/A |
| 52 Week Low | $11.73 | $2.83 |
| 52 Week High | $23.59 | $15.74 |
| Indicator | CLW | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 49.53 |
| Support Level | $20.28 | $3.44 |
| Resistance Level | $20.80 | $3.92 |
| Average True Range (ATR) | 0.86 | 0.08 |
| MACD | -0.26 | 0.00 |
| Stochastic Oscillator | 46.65 | 28.13 |
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.